Randomized Trialhigh evidence
Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.
Nature medicine·June 1, 2026·PMID 42260102
Why it mattersThis study suggests that SGLT2 inhibitors may provide substantial heart failure prevention in individuals with genetic cardiomyopathy risk, a group not previously studied in this context. It highlights a potential precision medicine approach to HF prevention in high-risk populations.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled